New study of hydroxychloroquine usage may help personalize lupus treatment
RI-MUHC researchers identify factors associated with poor outcomes for lupus patients
Reaching new heights by working together: Innovative industry partnership
RI-MUHC-led team will use artificial intelligence to improve survival rates of cancer-diagnosed patients
Two studies confirm efficiency of saliva tests for COVID-19
Testing is the cornerstone of the fight against COVID-19, and a test that can be self-administered would greatly increase the options for case...
Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper
New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples
Could an antidepressant slow COVID-19 progression?
RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...
Clinical Innovation Platform at the RI-MUHC announces first member company
Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility
Could a different testing strategy reduce healthcare workers’ isolation after unprotected exposure to a confirmed case of COVID-19?
RI-MUHC study suggests appropriate...
Haply wins the CODE LiFE Ventilator Challenge
What’s next? “Gather the resources to bring the Haply device to millions around the world,” says Reza Farivar
Researchers identify the origin of a deadly brain cancer
Finding could lead to potential therapies
The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients
Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects